Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729593 · ClinicalTrials.gov registry record · Phase 3
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
A Phase 3 study of COVID-19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT06729593: Completed Phase 3 study of COVID-19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06729593 is a Phase 3 study of COVID-19 that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 87 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06729593, a Phase 3 study of COVID-19, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.
Primary Outcome
The primary outcome was a 6-category ordinal outcome defining the participant's status at Day 90: (1) at home (defined as the type of residence before hospitalization) and off oxygen (recovered) for at least 77 days, (2) at home and off oxygen for 49-76 days, (3) at home and off oxygen for 1-48 days, (4) not hospitalized but either on supplemental oxygen or not at home, (5) hospitalized or in hospice care, or (6) dead.
Conditions Studied
Interventions
- DRUG Corticosteroid
- BIOLOGICAL Remdesivir
- BIOLOGICAL Remdesivir Placebo
Study Locations (20)
California
- UCSF Fresno (Site 203-005), 155 N. Fresno Street - Fresno
- VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street - Loma Linda
- Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Boulevard - Los Angeles
- Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza - Los Angeles
- UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. - San Francisco
- UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave. - San Francisco
- Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr. - Stanford
New York
- Mount Sinai Medical Center (Site 301-012), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place - New York
- Columbia University Irving Medical Center (Site 301-027), 177 Fort Washington Ave. - New York
- Montefiore Medical Center - Moses Hospital (Site 206-001), 111 E. 210th Street - The Bronx
- Montefiore Medical Center - Weiler campus (Site 206-003), 111 E. 210th Street - The Bronx
Colorado
- University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue - Aurora
- Denver Health Medical Center (Site 204-004), 780 Delaware Street, Pavilion B - Denver
District of Columbia
- MedStar Health Research Institute (Site 009-021), 110 Irving St., NW. - Washington D.C.
- Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW. - Washington D.C.
Massachusetts
- Massachusetts General Hospital (Site 202-002), 55 Fruit Street - Boston
- Baystate Medical Center (Site 201-001), Critical Care Research, 759 Chestnut Street - Springfield
Arizona
- Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue - Tucson
Georgia
- Emory University (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE. - Atlanta
North Carolina
- Duke University Hospital (Site 301-006), 2301 Erwin Road - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-11-20 |
| Phase | Phase 3 |
What the finished NCT06729593 record still lists
NCT06729593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Corticosteroid is the first listed.
NCT06729593 names 20 study sites across 8 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT06729593 about?
NCT06729593 is a clinical study titled "Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)". This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus curr...
What is the current status of trial NCT06729593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2021-04-20. Estimated completion is 2022-11-20.
What conditions does trial NCT06729593 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06729593?
The interventions under investigation include: Corticosteroid (DRUG), Remdesivir (BIOLOGICAL), Remdesivir Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06729593?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06729593 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06729593's enrollment target sits among peer trials
87 212th of 298 higher than 87 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI